Alemtuzumab-induced thyroid eye disease successfully treated with a single low dose of rituximab.

Ilaria Muller Sara Maioli Mirco Armenti Laura PorcaroNicola CurròElisabetta IofridaLorenzo PignataroJacopo MansoCaterina Mian Jens GeginatMario Salvi

Published in: European thyroid journal (2024)

RTX therapy successfully inactivated TED in a patient with low B-cell count derived from previous ALTZ treatment. B-cell depletion in both thyroid and peripheral blood was still present 1 year after RTX, indicating a likely cumulative effect of both treatments.

Keyphrases

peripheral blood
low dose
high glucose
case report
high dose
diffuse large b cell lymphoma
diabetic rats
stem cells
bone marrow
replacement therapy
mesenchymal stem cells
stress induced